FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022644166> ?p ?o ?g. }

• W2022644166 endingPage "528" @default.
• W2022644166 startingPage "522" @default.
• W2022644166 abstract "Purpose Proton therapy is an increasingly prominent radiation treatment modality. Market-driven adoption of proton therapy into routine clinical practice may have a significant economic impact. The aim of this study was to estimate the proportion of patients who could potentially be treated with proton therapy by evaluating the utilization of existing highly conformal photon therapy as a proxy. Methods All patients treated in 2007 with radiation therapy at the authors' institution were evaluated. Treatment technique was categorized using Current Procedural Terminology® codes as conventional radiation therapy, intensity-modulated radiation therapy, Gamma Knife radiosurgery, stereotactic body radiation therapy, and brachytherapy. Medicare 2008 codes were used to estimate cost impact. Results One thousand forty-two patients were treated using 19,749 treatment fractions. As a potential proxy for proton therapy, highly conformal external-beam photon techniques were delivered in 31% of all fractions (intensity-modulated radiation therapy in 30%, stereotactic body radiation therapy in <1%, and Gamma Knife radiosurgery in 1%). Most were used for prostate cancer (37%), gliomas (17%), and head and neck cancers (16%). Pediatric patients were a small proportion (2%) of treatments. Proton therapy, if delivered instead of highly conformal photon therapy, could increase annual cost for radiation therapy at the authors' institution by $1.3 million (22%) and require approximately 1.4 gantries to deliver. Conclusions Using existing utilization patterns of highly conformal photon therapy as a proxy, approximately one-third of patients irradiated annually at the authors' institution could be treated with proton therapy, with an incremental cost of 20% across the entire treated patient population. Proton therapy is an increasingly prominent radiation treatment modality. Market-driven adoption of proton therapy into routine clinical practice may have a significant economic impact. The aim of this study was to estimate the proportion of patients who could potentially be treated with proton therapy by evaluating the utilization of existing highly conformal photon therapy as a proxy. All patients treated in 2007 with radiation therapy at the authors' institution were evaluated. Treatment technique was categorized using Current Procedural Terminology® codes as conventional radiation therapy, intensity-modulated radiation therapy, Gamma Knife radiosurgery, stereotactic body radiation therapy, and brachytherapy. Medicare 2008 codes were used to estimate cost impact. One thousand forty-two patients were treated using 19,749 treatment fractions. As a potential proxy for proton therapy, highly conformal external-beam photon techniques were delivered in 31% of all fractions (intensity-modulated radiation therapy in 30%, stereotactic body radiation therapy in <1%, and Gamma Knife radiosurgery in 1%). Most were used for prostate cancer (37%), gliomas (17%), and head and neck cancers (16%). Pediatric patients were a small proportion (2%) of treatments. Proton therapy, if delivered instead of highly conformal photon therapy, could increase annual cost for radiation therapy at the authors' institution by $1.3 million (22%) and require approximately 1.4 gantries to deliver. Using existing utilization patterns of highly conformal photon therapy as a proxy, approximately one-third of patients irradiated annually at the authors' institution could be treated with proton therapy, with an incremental cost of 20% across the entire treated patient population." @default.
• W2022644166 created "2016-06-24" @default.
• W2022644166 creator A5018958736 @default.
• W2022644166 creator A5040475138 @default.
• W2022644166 date "2010-07-01" @default.
• W2022644166 modified "2023-09-30" @default.
• W2022644166 title "Evaluation of Potential Proton Therapy Utilization in a Market-Based Environment" @default.
• W2022644166 cites W172694461 @default.
• W2022644166 cites W1986376168 @default.
• W2022644166 cites W1991788167 @default.
• W2022644166 cites W2011051681 @default.
• W2022644166 cites W2012457048 @default.
• W2022644166 cites W2019553862 @default.
• W2022644166 cites W2019850432 @default.
• W2022644166 cites W2024142867 @default.
• W2022644166 cites W2030849413 @default.
• W2022644166 cites W2054729949 @default.
• W2022644166 cites W2055083549 @default.
• W2022644166 cites W2057242214 @default.
• W2022644166 cites W2083074823 @default.
• W2022644166 cites W2087449493 @default.
• W2022644166 cites W2100592197 @default.
• W2022644166 cites W2109110512 @default.
• W2022644166 cites W2125640401 @default.
• W2022644166 cites W2134552430 @default.
• W2022644166 cites W2147006378 @default.
• W2022644166 cites W2161324454 @default.
• W2022644166 cites W4243034093 @default.
• W2022644166 doi "https://doi.org/10.1016/j.jacr.2010.01.024" @default.
• W2022644166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20630388" @default.
• W2022644166 hasPublicationYear "2010" @default.
• W2022644166 type Work @default.
• W2022644166 sameAs 2022644166 @default.
• W2022644166 citedByCount "8" @default.
• W2022644166 countsByYear W20226441662012 @default.
• W2022644166 countsByYear W20226441662013 @default.
• W2022644166 countsByYear W20226441662014 @default.
• W2022644166 countsByYear W20226441662015 @default.
• W2022644166 countsByYear W20226441662016 @default.
• W2022644166 crossrefType "journal-article" @default.
• W2022644166 hasAuthorship W2022644166A5018958736 @default.
• W2022644166 hasAuthorship W2022644166A5040475138 @default.
• W2022644166 hasConcept C121608353 @default.
• W2022644166 hasConcept C126322002 @default.
• W2022644166 hasConcept C126838900 @default.
• W2022644166 hasConcept C141071460 @default.
• W2022644166 hasConcept C19527891 @default.
• W2022644166 hasConcept C2779244869 @default.
• W2022644166 hasConcept C2779513377 @default.
• W2022644166 hasConcept C2780192828 @default.
• W2022644166 hasConcept C2780387249 @default.
• W2022644166 hasConcept C509974204 @default.
• W2022644166 hasConcept C71924100 @default.
• W2022644166 hasConceptScore W2022644166C121608353 @default.
• W2022644166 hasConceptScore W2022644166C126322002 @default.
• W2022644166 hasConceptScore W2022644166C126838900 @default.
• W2022644166 hasConceptScore W2022644166C141071460 @default.
• W2022644166 hasConceptScore W2022644166C19527891 @default.
• W2022644166 hasConceptScore W2022644166C2779244869 @default.
• W2022644166 hasConceptScore W2022644166C2779513377 @default.
• W2022644166 hasConceptScore W2022644166C2780192828 @default.
• W2022644166 hasConceptScore W2022644166C2780387249 @default.
• W2022644166 hasConceptScore W2022644166C509974204 @default.
• W2022644166 hasConceptScore W2022644166C71924100 @default.
• W2022644166 hasIssue "7" @default.
• W2022644166 hasLocation W20226441661 @default.
• W2022644166 hasLocation W20226441662 @default.
• W2022644166 hasOpenAccess W2022644166 @default.
• W2022644166 hasPrimaryLocation W20226441661 @default.
• W2022644166 hasRelatedWork W1561685691 @default.
• W2022644166 hasRelatedWork W2036574567 @default.
• W2022644166 hasRelatedWork W2039595483 @default.
• W2022644166 hasRelatedWork W2092529223 @default.
• W2022644166 hasRelatedWork W2274455399 @default.
• W2022644166 hasRelatedWork W2900343598 @default.
• W2022644166 hasRelatedWork W3032687797 @default.
• W2022644166 hasRelatedWork W3097845695 @default.
• W2022644166 hasRelatedWork W3149555631 @default.
• W2022644166 hasRelatedWork W4210608052 @default.
• W2022644166 hasVolume "7" @default.
• W2022644166 isParatext "false" @default.
• W2022644166 isRetracted "false" @default.
• W2022644166 magId "2022644166" @default.
• W2022644166 workType "article" @default.